Literature DB >> 20305688

Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer.

S M Pontier1, L Huck, D E White, J Rayment, V Sanguin-Gendreau, B Hennessy, D Zuo, R St-Arnaud, G B Mills, S Dedhar, C J Marshall, W J Muller.   

Abstract

Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305688     DOI: 10.1038/onc.2010.86

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Authors:  C-R Pradeep; A Zeisel; W J Köstler; M Lauriola; J Jacob-Hirsch; B Haibe-Kains; N Amariglio; N Ben-Chetrit; A Emde; I Solomonov; G Neufeld; M Piccart; I Sagi; C Sotiriou; G Rechavi; E Domany; C Desmedt; Y Yarden
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

2.  Identification and characterization of a novel integrin-linked kinase inhibitor.

Authors:  Su-Lin Lee; En-Chi Hsu; Chih-Chien Chou; Hsiao-Ching Chuang; Li-Yuan Bai; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2011-08-24       Impact factor: 7.446

Review 3.  Integrins in development and cancer.

Authors:  Luke R Anderson; Thomas W Owens; Matthew J Naylor
Journal:  Biophys Rev       Date:  2013-10-17

4.  Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR.

Authors:  Bin Xiao; Dongmei Zuo; Alison Hirukawa; Robert D Cardiff; Richard Lamb; Nahum Sonenberg; William J Muller
Journal:  Cell Rep       Date:  2020-04-28       Impact factor: 9.423

Review 5.  Integrin signalling adaptors: not only figurants in the cancer story.

Authors:  Sara Cabodi; Maria del Pilar Camacho-Leal; Paola Di Stefano; Paola Defilippi
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

6.  beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression.

Authors:  L Huck; S M Pontier; D M Zuo; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

7.  Biochemical, proteomic, structural, and thermodynamic characterizations of integrin-linked kinase (ILK): cross-validation of the pseudokinase.

Authors:  Koichi Fukuda; James D R Knight; Grzegorz Piszczek; Rashmi Kothary; Jun Qin
Journal:  J Biol Chem       Date:  2011-04-26       Impact factor: 5.157

8.  Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.

Authors:  K Zhang; H Yao; Z Yang; D Li; L Yang; Q Zou; Y Yuan; X Miao
Journal:  Clin Transl Oncol       Date:  2016-02-18       Impact factor: 3.405

Review 9.  Integrin-linked kinase 1: role in hormonal cancer progression.

Authors:  Valerie Cortez; Binoj C Nair; Dimple Chakravarty; Ratna K Vadlamudi
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

10.  Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.

Authors:  Su-Lin Lee; Chih-Chien Chou; Hsiao-Ching Chuang; En-Chi Hsu; Po-Chen Chiu; Samuel K Kulp; John C Byrd; Ching-Shih Chen
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.